Switch from abciximab to eptifibatide during percutaneous coronary intervention

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Pharmacology

Background:

• Glycoprotein (GP) IIb/IIIa inhibitors are crucial for reducing ischemic complications during percutaneous coronary intervention (PCI).
• Abciximab is well-documented but more expensive than eptifibatide.
• This study investigates the clinical outcomes following a switch from abciximab to eptifibatide.

Purpose of the Study:

• To evaluate the clinical outcomes up to six months after switching from abciximab to eptifibatide for GPIIb/IIIa inhibition during PCI.
• To compare the safety and efficacy of eptifibatide versus abciximab in a real-world clinical setting.

Main Methods:

• A cohort study followed 660 patients undergoing de novo PCI.
• Patients received either abciximab (n=310) or eptifibatide (n=350) for GPIIb/IIIa inhibition.
• Clinical outcomes were assessed up to six months post-PCI, comparing patients before and after the drug switch.

Main Results:

• Baseline characteristics were similar between the abciximab and eptifibatide groups.
• Trends suggested lower in-hospital (0.6% vs 2.0%) and six-month mortality (2.3% vs 3.7%) with abciximab, though not statistically significant (NS).
• The combined endpoint of death, myocardial infarction, stroke, revascularization, and bleeding occurred in 14.9% (abciximab) vs 16.8% (eptifibatide) (NS).

Conclusions:

• No significant clinical outcome deterioration was observed after switching from abciximab to eptifibatide for routine GPIIb/IIIa inhibition during PCI.
• A clinically significant difference between the two agents cannot be excluded due to the limited sample size.
• Eptifibatide appears to be a viable alternative to abciximab in this patient population.